Yiyi biology has reached an exclusive strategic cooperation with Zhengda Tianqing to promote the commercialization of a new generation of long-term G-CSF in China

Yiouda health news on August 30, Yiyi biology and Zhengda Tianqing on f-627 (American trade name ryzneuta) ™） In order to reach strategic cooperation in China's commercialization, Yiyi biological exclusively authorizes the Chinese commercialization rights and interests of the new biological drug f-627 to Zhengda Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., a core subsidiary of China biopharmaceutical, which will obtain a down payment and milestone payment of up to 210 million yuan, as well as a two-digit graded net sales royalty. F-627 is a biological innovative drug for neutropenia (CIN) caused by chemotherapy. CIN is a common side effect of various chemotherapy, which is easy to increase the risk of adverse reactions such as infection and fever. Granulocyte colony stimulating factor (G-CSF) is the first therapeutic drug in clinical guidelines at home and abroad, commonly known as the gold standard. F-627 solves the problem in one step. Based on Fc fusion protein technology, rhG CSF dimer expressed by CHO cells is easier to form G-CSF ligand receptor dimer complex in spatial structure, so as to enhance affinity and have long-term and powerful biological properties. So far, Yiyi has recruited more than 1200 patients in many countries and regions, including the United States, the European Union, Australia and China, covering the main first-line chemotherapy drugs. It is the only long-acting G-CSF in the world that has conducted head-to-head comparative tests with the original long-acting (peferistine) and short-acting G-CSF (feferistine). Currently undergoing FDA BLA review.